Recent studies show that Desulfovibrionales are enriched in cholelithiasis patients, increase the synthesis of secondary BAs and intestinal cholesterol uptake, stimulate biliary secretion, and affect FXR and CYP7A expression [15]. The gene discussed is NR1H4; the disease is cholelithiasis.